Trial Profile

A single-arm, open-label, multicenter, phase II clinical study on the efficacy and safety of DNV3 in combination with toripalimab and chemotherapy in patients with locally advanced unresectable/metastatic melanoma who have failed immune checkpoint inhibitor therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; DNV 3 (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
Indications Acral lentiginous melanoma; Malignant melanoma
Focus Therapeutic Use
Acronyms ChiCTR2400091269; CTM-2024-8; CTR20243964

01 Apr 2026 New trial record
23 Jul 2025 According to CentryMed media release, data from this trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
26 Jun 2025 According to CentryMed media release, data from this trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com